Browse > Article
http://dx.doi.org/10.3339/jkspn.2019.23.2.93

Pathology of C3 Glomerulopathy  

Shin, Su-Jin (Department of Pathology, Yonsei University College of Medicine)
Seong, Yoonje (Department of Pathology, Yonsei University College of Medicine)
Lim, Beom Jin (Department of Pathology, Yonsei University College of Medicine)
Publication Information
Childhood Kidney Diseases / v.23, no.2, 2019 , pp. 93-99 More about this Journal
Abstract
C3 glomerulopathy is a renal disorder involving dysregulation of alternative pathway complement activation. In most instances, a membranoproliferative pattern of glomerular injury with a prevalence of C3 deposition is observed by immunofluorescence microscopy. Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are subclasses of C3 glomerulopathy that are distinguishable by electron microscopy. Highly electron-dense transformation of glomerular basement membrane is characteristic of DDD. C3GN should be differentiated from post-infectious glomerulonephritis and other immune complex-mediated glomerulonephritides showing C3 deposits.
Keywords
C3 glomerulopathy; C3 glomerulonephritis; Membranoproliferative glomerulonephritis; Dense deposit disease; Alternative complement pathway;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013;24:1820-9.   DOI
2 Corvillo F, Okroj M, Nozal P, Melgosa M, Sanchez-Corral P, Lopez-Trascasa M. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol 2019;10:886.   DOI
3 Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulonephritis with a severe crescentic phenotype. Pediatr Nephrol 2017;32:1625-33.   DOI
4 Michels M, van de Kar N, van den Bos RM, van der Velden T, van Kraaij SAW, Sarlea SA, et al. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Front Immunol 2019;10:1350.   DOI
5 Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, et al. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 2017;92:1232-41.   DOI
6 Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, et al. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. Am J Kidney Dis 2017;70:834-43.   DOI
7 Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc 2018;93:991-1008.   DOI
8 Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015;194:5129-38.   DOI
9 Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, et al. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. J Am Soc Nephrol 2017;28:1603-13.   DOI
10 Prema KSJ, Kurien AA, Gopalakrishnan N, Walker PD, Larsen CP. Dense deposit disease: a greatly increased biopsy incidence in India versus the USA. Clin Kidney J 2019;12:476-82.   DOI
11 Park SJ, Kim YJ, Ha TS, Lim BJ, Jeong HJ, Park YH, et al. Dense deposit disease in Korean children: a multicenter clinicopathologic study. J Korean Med Sci 2012;27:1215-21.   DOI
12 Sethi S, Fervenza FC, Smith RJ, Haas M. Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney Int 2015;88:1449-50.
13 Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015;11:14-22.   DOI
14 Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011;6:1009-17.   DOI
15 Bridoux F, Desport E, Fremeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011;6:2165-74.   DOI
16 Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan SM, et al. Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. Clin Kidney J 2016;9:397-402.   DOI
17 Ito N, Ohashi R, Nagata M. C3 glomerulopathy and current dilemmas. Clin Exp Nephrol 2017;21:541-51.   DOI
18 Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89.   DOI
19 Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol 2010;25:1409-18.   DOI
20 Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A 2013;110:4685-90.   DOI
21 Strife CF, McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 1977;7:65-72.
22 Levy M, Gubler MC, Sich M, Beziau A, Habib R. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978;10:477-92.   DOI
23 Habib R, Gubler MC, Loirat C, Maiz HB, Levy M. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int 1975;7:204-15.   DOI
24 Burkholder PM, Marchand A, Krueger RP. Mixed membranous and proliferative glomerulonephritis. A correlative light, immunofluorescence, and electron microscopic study. Lab Invest 1970;23:459-79.
25 Anders D, Agricola B, Sippel M, Thoenes W. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch A Pathol Anat Histol 1977;376:1-19.   DOI
26 Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009;4:22-32.   DOI
27 Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 2007;20:605-16.   DOI
28 Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, et al. C3 glomerulopathy - understanding a rare complementdriven renal disease. Nat Rev Nephrol 2019;15:129-43.   DOI
29 Belgiojoso GB, Tarantino A, Bazzi C, Colasanti G, Guerra L, Durante A. Immunofluorescence patterns in chronic membranoproliferative glomerulonephritis (MPGN). Clin Nephrol 1976;6:303-10.
30 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23.   DOI
31 Strife CF, West CD, Witte DP. Crescentic glomerulonephritis in childhood: acute nonproliferative glomerulitis versus dense deposit disease. Am J Kidney Dis 2003;41:897; author reply 8.   DOI
32 Sawanobori E, Umino A, Kanai H, Matsushita K, Iwasa S, Kitamura H, et al. A prolonged course of Group A streptococcus-associated nephritis: a mild case of dense deposit disease (DDD)? Clin Nephrol 2009;71:703-7.   DOI
33 Okabe M, Tsuboi N, Yokoo T, Miyazaki Y, Utsunomiya Y, Hosoya T. A case of idiopathic membranoproliferative glomerulonephritis with a transient glomerular deposition of nephritis-associated plasmin receptor antigen. Clin Exp Nephrol 2012;16:337-41.   DOI
34 Hawf ield A, Iskandar SS, Smith RJ. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy. Am J Kidney Dis 2013;61:828-31.   DOI
35 Churg J, Duffy JL, Bernstein J. Identification of dense deposit disease: a report for the International Study of Kidney Diseases in Children. Arch Pathol Lab Med 1979;103:67-72.
36 Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53.   DOI
37 Sethi S, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic Tool in Proliferative GN. J Am Soc Nephrol. 2015;26:2852-9.   DOI
38 Kanjanabuch T, Kittikowit W, Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 2009;5:259-69.   DOI
39 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51.   DOI
40 Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013;83:293-9.   DOI
41 Fish AJ, Herdman RC, Michael AF, Pickering RJ, Good RA. Epidemic acute glomerulonephritis associated with type 49 streptococcal pyoderma. II. Correlative study of light, immunofluorescent and electron microscopic findings. Am J Med 1970;48:28-39.   DOI
42 Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012;82:465-73.   DOI
43 Sandhu G, Bansal A, Ranade A, Jones J, Cortell S, Markowitz GS. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis 2012;60:1039-43.   DOI
44 Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94:178-86.   DOI
45 Vernon KA, Goicoechea de Jorge E, Hall AE, Fremeaux-Bacchi V, Aitman TJ, Cook HT, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 2012;60:121-5.   DOI
46 Suga K, Kondo S, Matsuura S, Kinoshita Y, Kitano E, Hatanaka M, et al. A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency. Pediatr Nephrol 2010;25:1547-50.   DOI
47 Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). Eur J Pediatr 2014;173:767-72.   DOI
48 Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez- Martul E, Torreira E, Montes T, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702-12.   DOI
49 Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011;20:271-7.   DOI
50 Sethi S, Rajkumar SV, D'Agati VD. The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol. 2018;29:1810-23.   DOI
51 Bomback AS, Markowitz GS, Appel GB. Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney Int Rep 2016;1:148-55.   DOI
52 Pickering RJ, Herdman RC, Michael AF, Vernier RL, Gewurz H, Fish AJ, et al. Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis). Medicine (Baltimore) 1970;49:207-26.   DOI
53 Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9.   DOI
54 Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol 2013;33:479-92.   DOI
55 Cook HT. C3 glomerulopathy. F1000Res 2017;6:248.   DOI
56 Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens 2016;25:127-37.   DOI
57 Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014;85:450-6.   DOI
58 Yagi K, Yanagida H, Sugimoto K, Kuwajima H, Tabata N, Morita K, et al. Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis. Pediatr Nephrol 2005;20:1273-8.   DOI
59 Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon- Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64.   DOI
60 Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, et al. Clinico-pathologic spectrum of C3 glomerulopathyan Indian experience. Diagn Pathol 2015;10:6.   DOI
61 Jozsi M, Reuter S, Nozal P, Lopez-Trascasa M, Sanchez-Corral P, Prohaszka Z, et al. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol Lett 2014;160:163-71.   DOI
62 Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: Is C3 a contact-activated protein? Immunobiology 2012;217:1106-10.   DOI
63 Wong EKS, Kavanagh D. Diseases of complement dysregulationan overview. Semin Immunopathol 2018;40:49-64.   DOI
64 Spitzer RE, Stitzel AE, Tsokos GC. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin Immunol Immunopathol 1990;57:10-8.   DOI
65 Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Cordoba SR, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012;82:1084-92.   DOI
66 Ito S, Tamura N, Fujita T. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor. Immunology 1989;68:449-52.